Natural antibodies: Protecting role of IgM in glioblastoma and brain tumours

Semwal, Shubham; Boukherroub, Rabah; Savvides, Savvas; Bouckaert, Julie

Type de document :

Article dans une revue scientifique

DOI :

10.2174/1381612827666210728103524

URL permanente :

http://hdl.handle.net/20.500.12210/55894

Titre :

Natural antibodies: Protecting role of IgM in glioblastoma and brain tumours

Auteur(s) :

Semwal, Shubham [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle (UGSF) - UMR 8576
Boukherroub, Rabah [Auteur]

Institut d'Électronique, de Microélectronique et de Nanotechnologie (IEMN) - UMR 8520
Savvides, Savvas [Auteur]
Bouckaert, Julie [Auteur]

Unité de Glycobiologie Structurale et Fonctionnelle (UGSF) - UMR 8576

Titre de la revue :

Current Pharmaceutical Design

Nom court de la revue :

CPD

Éditeur :

Bentham Science Publishers Ltd.

Date de publication :

2021-07-28

ISSN :

1381-6128

Mot(s)-clé(s) en anglais :

IgM
Glioblastoma
Natural Antibodies
Immunotherapy
Microglia
ALK

Discipline(s) HAL :

Sciences du Vivant [q-bio]
Chimie/Chimie théorique et/ou physique

Résumé en anglais : [en]

Background: Glioblastoma is a grade IV astrocytoma with an average survival span for patients of 18 months after initial diagnosis and no standard treatment protocol. There is a need to look at novel approaches to target ...
Lire la suite >Background: Glioblastoma is a grade IV astrocytoma with an average survival span for patients of 18 months after initial diagnosis and no standard treatment protocol. There is a need to look at novel approaches to target glioblastoma. Objectives: This review intends to capture the role of immunoglobulin-M in cancer, more specifically in glioblastoma multiforme (GBM), and to compile the latest developments and immunological pathways relevant to glioblastoma Methods: Information on glioblastoma, cancer microenvironment, cancer therapeutics and how to improve the scenario was obtained from scientific literature databases such as Pubmed, Medline, Google Scholar, Science Direct, Springer, Wiley online library and some data was harvested from regulatory and compliance databases such as clinicaltrials.gov, FDA database, WHO Globocan. Results and Conclusions: Currently, only a limited number of therapies are approved for GBM, and no standard of care is in place in case of disease relapse, necessitating a possible broader perspective in looking at the disease and its underlying mechanisms.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Projet Européen :

Programme for EArly-stage Researchers in Lille

Établissement(s) :

Université de Lille
CNRS

Collections :

Unité de Glycobiologie Structurale et Fonctionnelle (UGSF) - UMR 8576

Équipe(s) de recherche :

Computational Molecular Systems Biology

Date de dépôt :

2021-10-14T14:37:25Z
2021-10-18T07:59:20Z
2022-03-07T11:32:48Z
2022-10-21T14:51:29Z

Fichiers

P21.29 Bouckaert_Manuscript_Revised.pdf
Version soumise (preprint)
Accès libre
Accéder au document

Historique des modifications

Numéro de version	Lien	Date de modification
4	20.500.12210/55894*	2022-10-21T14:51:08Z
3	20.500.12210/55894.3	2022-03-07T11:28:47Z
2	20.500.12210/55894.2	2021-10-18T07:52:53Z
1	20.500.12210/55894.1	2021-10-14T14:37:25Z

*Version sélectionnée

Natural antibodies: Protecting role of IgM ... BibTeX CSV Excel RIS

Fichiers

Historique des modifications

Natural antibodies: Protecting role of IgM ...

BibTeX

CSV

Excel

RIS